GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS Axis in hepatocellular carcinoma

5-FU is a common first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma. However the development of acquired resistance to 5-FU confines its clinical usages. Although this phenomenon has been the subject of intense investigation, the exact mechanism of acquired resistance to...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Gu, Yan-jiao, Li, Hong-dan, Zhao, Liang, Zhao, Song, He, Wu-bin, Rui, Li, Su, Chang, Zheng, Hua-chuan, Su, Rong-jian
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741793/
https://ncbi.nlm.nih.gov/pubmed/26378040
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы